Big biotech, Biotech, Partnering, Pharma

Genmab and Seattle Genetics become biotech partners for developing ADC

Posted on 11 September 2014

Tags: , ,

Seattle Genetics becomes a biotech partner of Genmab for developing antibody-drug conjugate (ADC).

Genmab will pay $11 million for exclusive rights to Seattle Genetics’ ADC technology with Genmab’s HuMax, an antibody targeting AXL, which is present in multiple types of solid cancers.

Seattle Genetics will also become entitled to receive $200 million in potential milestone payments and mid-to-high single digit royalties on worldwide net sales of resulting products.

The company will have the right to exercise an option to increase the royalties to double digits in exchange for the reduction of milestone payments owed by Genmab in the event of a Phase 3 study for new products.

For further deal information visit Current Agreements (subscription required)


Report: Monoclonal Antibodies Partnering Terms and Agreements

Report: Antibody Partnering Terms and Agreements

Browse: Complete Current Partnering report catalogue

View: Partnering Scorecard in CP Insight– view top life science partnering deals by value

View: Partnering’s DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply